NS‐398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines
Open Access
- 14 May 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 99 (5) , 755-761
- https://doi.org/10.1002/ijc.10409
Abstract
Cyclooxygenase 2 (COX-2) has been suggested to be associated with liver carcinogenesis. Several reports have shown that NSAIDs inhibit the growth of hepatocellular carcinoma cell lines. There is little evidence of how COX-2 inhibitors regulate the proliferation of hepatocellular carcinoma cells or the mechanism involved. In our study, we investigated the growth-inhibitory mechanism of a selective COX-2 inhibitor, NS-398, in 4 hepatocellular carcinoma cell lines by studying cell growth, COX-2 and proliferating cell nuclear antigen (PCNA) expression, cell cycle distribution and the evidence of apoptosis. NS-398 inhibited the growth of all 4 cell lines in a time- and dose-dependent manner and the inhibitory effects were independent of the level of COX-2 protein expression. PCNA expression was downregulated by NS-398 in a dose-independent manner. NS-398 caused cell cycle arrest in the S phase with a reduction in cell numbers and cell accumulation in the G0/G1 phase, for all 4 cell lines. No evidence of apoptosis was observed in our present study. Our findings suggest that a selective COX-2 inhibitor might serve as an effective tool for the chemoprevention and treatment of hepatocellular carcinomas. A reduction in cell number in the S phase may be an important event in cell cycle arrest caused by NS-398 in hepatocellular carcinoma cell lines.Keywords
This publication has 20 references indexed in Scilit:
- Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma CellsJournal of Biological Chemistry, 2001
- Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL–10−/− miceGastroenterology, 2000
- Cyclooxygenase‐2 (COX‐2) mRNA Expression Levels in Normal Lung Tissues and Non‐small Cell Lung CancersJapanese Journal of Cancer Research, 1999
- Sulindac Inhibits Activation of the NF-κB PathwayJournal of Biological Chemistry, 1999
- Sulindac sulfide inhibits Ras signalingOncogene, 1998
- PCNA: structure, functions and interactionsOncogene, 1997
- Requirement of proliferating cell nuclear antigen in RAD6-dependent postreplicational DNA repair.Proceedings of the National Academy of Sciences, 1996
- Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.Journal of Clinical Investigation, 1995
- Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: The effect of sulindacJournal of Surgical Oncology, 1995
- Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.The Journal of cell biology, 1987